Sonnet BioTherapeutics (NASDAQ:SONN) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team
Express News | Sonnet Biotherapeutics Holdings Inc - Son-080 Well-Tolerated at Both Doses
Express News | Sonnet Biotherapeutics Reports Encouraging Data From Phase 1B/2a Clinical Trial of Son-080 in Chemotherapy-Induced Peripheral Neuropathy (Cipn) That Support Advancement Into Phase 2 Study
Sonnet Bio Therapeutics Files to Sell 5.77M Shares of Common Stock for Holders
12 Health Care Stocks Moving In Friday's Pre-Market Session
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
12 Health Care Stocks Moving In Thursday's Intraday Session
Sonnet BioTherapeutics Announces Exercise of Warrants for $3.4 Million in Gross Proceeds
Express News | Sonnet Biotherapeutics - Il-18 Clinical Trials Have Shown That, Although It Is Well Tolerated, Il-18 Has Poor Efficacy in Treatment of Cancers
Express News | Sonnet Biotherapeutics- Il-18(Bpr) Was Linked to Sonnet's Proprietary Tumor Targeting F(H)AB Platform, With or Without Single-Chain Wild-Type Il-12
Express News | Sonnet Biotherapeutics Holdings Inc - Il-18(Bpr) and Il-12 Could Be Combined for Broad Applications in Oncology and Cell-Based Therapies
Express News | Sonnet Biotherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, Son-1411 and Son-1400, Each Containing a Variant Il-18 Domain
Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting
Sonnet BioTherapeutics Is Maintained at Buy by Chardan Capital
Chardan Capital Maintains Buy on Sonnet BioTherapeutics, Maintains $30 Price Target
Express News | Sonnet Biotherapeutics - Board Initiated Process to Explore and Review a Range of Strategic Alternatives Focused on Maximizing Stockholder Value
Express News | Sonnet Biotherapeutics Holdings Inc - Announces Review of Strategic Alternatives
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined With an Anti-PD-L1, Along With an Increase in the Dose-Escalation Target
Sonnet BioTherapeutics Is Maintained at Buy by EF Hutton
EF Hutton: Maintains Sonnet BioTherapeutics (SONN.US) rating, adjusted from buy to buy rating, and adjusted target price from $11.00 to $7.00.
EF Hutton: Maintains Sonnet BioTherapeutics (SONN.US) rating, adjusted from buy to buy rating, and adjusted target price from $11.00 to $7.00.
No Data